Is the future of diabetes treatment better drugs or better care?

Drug manufacturers are trying to push the boundaries of glucose control, but cost concerns could rein in ambitions.

By Jonathan Gardner • Sept. 23, 2019

Regulatory barriers limit alternative state drug payment models

Forced to balance higher costs with public health goals, more states are looking at alternative payment models for prescription drugs in Medicaid.

By Samantha Liss • Sept. 18, 2019

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

J&J finds competitive edge with latest Erleada approval

The advantage may be short-lived, however, as a rival prostate cancer drug from Pfizer could notch a similar approval in the fourth quarter.

By Jacob Bell • Sept. 18, 2019

Vertex makes headway in UK reimbursement

Scotland has agreed to cover two Vertex drugs, Orkambi and Symkevi, which may bode well for resolving a dispute over the company's prices.

By Jacob Bell • Sept. 12, 2019

Survey suggests Ionis is losing battle against Pfizer and Alnylam

Physician preferences between the company's respective drugs appear to be emerging in the year since Ionis' Tegsedi won approval. 

By Jacob Bell • Sept. 10, 2019

Pharma's reputation among Americans sinks to lowest level in decades: poll

According to Gallup, Americans even view the federal government more favorably than biopharma, which ranks as the most poorly regarded industry.

By Kristin Jensen • Sept. 4, 2019

Novartis secures NICE nod for Luxturna with discount offer

The U.K. cost agency recommended Luxturna after reaching a deal with Novartis, which sells the Spark gene therapy outside the U.S.

By Ned Pagliarulo • Sept. 4, 2019

Skyrizi looks ready to soar after strong launch

Dermatologists expect Skyrizi prescriptions to accelerate, according to a new survey that has some analysts now forecasting $300 million in 2019 sales for the psoriasis drug.

By Jacob Bell • Sept. 4, 2019

Unblinded: Rebekah Gee's drug pricing experiment in Louisiana

Louisiana's health secretary negotiated a new payment model with Gilead for one of the poorest states in the country. Could it spread nationwide?

By Andrew Dunn • Aug. 28, 2019

Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds

Out-of-pocket spending on MS medications increased by more than 600% in the decade from 2006 to 2016, while the typical list price quadrupled.

By Andrew Dunn • Aug. 27, 2019

Pharmacogenetic test makers cheer UnitedHealth coverage. Other payers aren't there yet.

"I've been concerned that the hype around pharmacogenetics, at least for depression, has gotten out ahead of the data," said one psychiatry expert at Johns Hopkins.

By Graison Dangor • Aug. 27, 2019

Lilly's case for Taltz helped by expanded approval

By prescription numbers, Taltz trails Novartis' rival drug Cosentyx. An approval for use in ankylosing spondylitis will go some ways to level the playing field.

By Ned Pagliarulo • Aug. 26, 2019

Today's data linkage is tomorrow's privacy breach

Is your company at risk?

By Crossix Solutions • Aug. 22, 2019

Trump administration not giving up on plan to require prices in TV drug ads

Amgen, Merck and Eli Lilly successfully blocked the rule from taking effect in July, winning a district court decision that HHS is now appealing. 

By Ned Pagliarulo • Aug. 21, 2019

NHS coverage opens up Hemlibra to thousands more patients

The decision could help Roche's hemophilia drug make headway in the European market, especially among patients without inhibitors.

By Jacob Bell • Aug. 21, 2019

Amgen biosimilar debut boosted by UnitedHealthcare coverage switch

Recently launched Mvasi and Kanjinti, copycat versions of Avastin and Herceptin respectively, will be preferred products for the insurer starting October 1. 

By Ned Pagliarulo • Updated Aug. 19, 2019

Nonprofit under pressure to make new TB drug affordable

Doctors Without Borders is calling on the TB Alliance to set a low price for the drug, and to put money from a sale of a regulatory fast pass toward patient access.

By Jacob Bell • Aug. 15, 2019

Gilead's Descovy set for PrEP approval, but not without data, access concerns

An expert panel recommended the FDA extend approval of Gilead's drug for preventive use, though advisers pushed for further study in cisgender women.

By Jacob Bell • Aug. 8, 2019

Regulators, Gilead at odds over HIV drug's use in women

An expert panel today will discuss Gilead's application for Descovy's use as a preventive treatment for HIV.

By Jacob Bell • Aug. 5, 2019

Congress is going after drug prices. Pharma CEOs aren't panicking, yet

A Senate Finance bill could emerge as the most palatable option for an industry seeking to limit losses in an election cycle already targeting pricing as an issue.

By Ned Pagliarulo • Aug. 2, 2019

White House backs importing drugs from abroad

The Trump administration's latest drug price plan features ideas Republicans traditionally oppose and breaks with past claims about the FDA's ability to safely oversee importation.

By Jonathan Gardner • July 31, 2019

Does your brand need behavioral science?

Does your brand need a behavioral science solution? Find the right solution to meet your needs.

By Meredith Terry, PhD Lead Behaviorist, Innovation and Practice MicroMass Communications, Inc. • July 31, 2019

Sales gap grows between rival Merck, Bristol cancer therapies

Keytruda posted $2.6 billion in sales during the second quarter, spurring Merck to substantially boost its revenue projections for the year.

By Ned Pagliarulo • July 30, 2019

FTC probing J&J on Remicade, as biosimilar market remains muted

The anti-inflammation drug has held onto its market share despite years of biosimilar competition. Now, the FTC wants to know how.

By Andrew Dunn • July 30, 2019

European regulators back Bayer, GW drugs, but with caveats

The CHMP recommended conditional approval of Vitrakvi while also advising Epidiolex be used as adjunctive therapy, an opinion one analyst described as "disappointing."

By Jacob Bell • July 26, 2019